Brandywine Global Investment Management LLC boosted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 780,307 shares of the medical research company’s stock after acquiring an additional 19,528 shares during the quarter. Amgen comprises about 1.1% of Brandywine Global Investment Management LLC’s portfolio, making the stock its 17th largest position. Brandywine Global Investment Management LLC’s holdings in Amgen were worth $151,903,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Amgen by 2.0% in the 4th quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock valued at $8,979,621,000 after buying an additional 906,568 shares during the period. Oregon Public Employees Retirement Fund increased its stake in Amgen by 20,103.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after buying an additional 31,268,677 shares in the last quarter. Northern Trust Corp increased its stake in Amgen by 4.7% during the 4th quarter. Northern Trust Corp now owns 9,182,050 shares of the medical research company’s stock worth $1,787,470,000 after buying an additional 408,675 shares in the last quarter. Geode Capital Management LLC increased its stake in Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after buying an additional 482,760 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in Amgen by 36.2% during the 3rd quarter. AQR Capital Management LLC now owns 2,907,575 shares of the medical research company’s stock worth $602,711,000 after buying an additional 773,506 shares in the last quarter. 79.18% of the stock is owned by institutional investors.

In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total value of $377,760.00. Following the transaction, the director now directly owns 14,988 shares in the company, valued at $2,830,933.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 6,000 shares of company stock worth $1,144,120 over the last quarter. 0.27% of the stock is currently owned by insiders.

Several equities research analysts have commented on the company. Mizuho set a $208.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Friday. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research note on Monday. BidaskClub lowered Amgen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Royal Bank of Canada restated a “neutral” rating and set a target price on shares of Amgen in a report on Monday, January 14th. Finally, Morgan Stanley lowered their target price on Amgen from $213.00 to $212.00 and set an “overweight” rating on the stock in a report on Wednesday, December 19th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $209.11.

Shares of Amgen stock opened at $191.20 on Tuesday. The company has a market cap of $117.91 billion, a PE ratio of 13.28, a P/E/G ratio of 2.35 and a beta of 1.21. Amgen, Inc. has a 1-year low of $165.22 and a 1-year high of $210.19. The company has a debt-to-equity ratio of 2.36, a quick ratio of 2.57 and a current ratio of 2.79.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.26 by $0.16. Amgen had a return on equity of 66.74% and a net margin of 35.35%. The firm had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $5.88 billion. During the same period in the prior year, the firm posted $2.89 earnings per share. As a group, analysts expect that Amgen, Inc. will post 13.97 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is presently 40.28%.

ILLEGAL ACTIVITY WARNING: “Brandywine Global Investment Management LLC Raises Holdings in Amgen, Inc. (AMGN)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2019/04/16/brandywine-global-investment-management-llc-raises-holdings-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: Short Selling Stocks and Day Traders

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.